139 related articles for article (PubMed ID: 31000447)
1. Benign differentiation of treated neuroblastoma as a cause of false positive by
Garcia JR; Bassa P; Soler M; Jaramillo A; Ortiz S; Riera E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(6):389-390. PubMed ID: 31000447
[No Abstract] [Full Text] [Related]
2. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
3. [
Wang P; Li T; Liu Z; Jin M; Su Y; Zhang J; Jing H; Zhuang H; Li F
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3097-3106. PubMed ID: 37160439
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
[TBL] [Abstract][Full Text] [Related]
5. ¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma.
Melzer HI; Coppenrath E; Schmid I; Albert MH; von Schweinitz D; Tudball C; Bartenstein P; Pfluger T
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1648-58. PubMed ID: 21617976
[TBL] [Abstract][Full Text] [Related]
6. Abnormal FDG and MIBG Activity in the Bones in a Patient With Neuroblastoma Without Detectable Primary Tumor.
Zhang W; Zhuang H; Servaes S
Clin Nucl Med; 2016 Aug; 41(8):632-3. PubMed ID: 26825196
[TBL] [Abstract][Full Text] [Related]
7. [Neuroblastoma staging: discrepancies between ¹⁸F-FDG-PET and ¹²³I-MIBG].
Mena LM; Muros MA; Palacios H; Moreno MJ; Santiago A; Llamas JM
An Pediatr (Barc); 2010 Dec; 73(6):363-4. PubMed ID: 20817583
[No Abstract] [Full Text] [Related]
8. Neuroblastoma Presenting as Non-MIBG-Avid Widespread Soft Tissue Metastases Without Bone Involvement Revealed by FDG PET/CT Imaging.
Tolboom N; Servaes SE; Zhuang H
Clin Nucl Med; 2017 Aug; 42(8):643-644. PubMed ID: 28525450
[TBL] [Abstract][Full Text] [Related]
9. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
Sharp SE; Shulkin BL; Gelfand MJ; Salisbury S; Furman WL
J Nucl Med; 2009 Aug; 50(8):1237-43. PubMed ID: 19617326
[TBL] [Abstract][Full Text] [Related]
10. Superiority of SPECT/CT over planar 123I-mIBG images in neuroblastoma patients with impact on Curie and SIOPEN score values.
Černý I; Prášek J; Kašpárková H
Nuklearmedizin; 2016 Aug; 55(4):151-7. PubMed ID: 27054367
[TBL] [Abstract][Full Text] [Related]
11. Predicting event-free survival after induction of remission in high-risk pediatric neuroblastoma: combining
Feng L; Yang X; Wang C; Zhang H; Wang W; Yang J
Pediatr Radiol; 2024 May; 54(5):805-819. PubMed ID: 38492045
[TBL] [Abstract][Full Text] [Related]
12. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative.
Mc Dowell H; Losty P; Barnes N; Kokai G
Pediatr Blood Cancer; 2009 Apr; 52(4):552. PubMed ID: 19058210
[No Abstract] [Full Text] [Related]
13. Multiple Endocrine Neoplasia Type 2B Unmasked by 18 F-FDG PET/CT and 131 I-MIBG SPECT/CT.
Sun X; Arnous MM; Lan X
Clin Nucl Med; 2017 Apr; 42(4):297-299. PubMed ID: 28134695
[TBL] [Abstract][Full Text] [Related]
14.
Aboian MS; Huang SY; Hernandez-Pampaloni M; Hawkins RA; VanBrocklin HF; Huh Y; Vo KT; Gustafson WC; Matthay KK; Seo Y
J Nucl Med; 2021 Jan; 62(1):43-47. PubMed ID: 32414950
[TBL] [Abstract][Full Text] [Related]
15. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
[TBL] [Abstract][Full Text] [Related]
16. Combining 123I-metaiodobenzylguanidine SPECT/CT and 18F-FDG PET/CT for the assessment of brown adipose tissue activity in humans during cold exposure.
Admiraal WM; Holleman F; Bahler L; Soeters MR; Hoekstra JB; Verberne HJ
J Nucl Med; 2013 Feb; 54(2):208-12. PubMed ID: 23318291
[TBL] [Abstract][Full Text] [Related]
17. [
Samim A; Blom T; Poot AJ; Windhorst AD; Fiocco M; Tolboom N; Braat AJAT; Viol SLM; van Rooij R; van Noesel MM; Lam MGEH; Tytgat GAM; de Keizer B
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1146-1157. PubMed ID: 36504277
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
[TBL] [Abstract][Full Text] [Related]
19. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
Nguyen NC; Bhatla D; Osman MM
J Nucl Med; 2010 Feb; 51(2):330-1; author reply 331. PubMed ID: 20080890
[No Abstract] [Full Text] [Related]
20. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative.
Colavolpe C; Guedj E; Cammilleri S; Taïeb D; Mundler O; Coze C
Pediatr Blood Cancer; 2008 Dec; 51(6):828-31. PubMed ID: 18680162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
